台灣臨床試驗主持人資料庫|TPIDB

2018-12-25 - 2024-07-04

Phase III

Completed

Condition/Disease
Test Drug

Participate Sites
6Sites

Recruiting4Sites

Terminated1Sites

吳宜珍

Kaohsiung Municipal Gangshan Hospital

未分科

2019-03-14 - 2025-06-30

Phase III

Completed

Condition/Disease
Test Drug

Participate Sites
6Sites

Terminated5Sites

邱世欣

Kaohsiung Municipal Gangshan Hospital

未分科

2016-09-19 - 2019-08-23

Phase II/III

Completed

Condition/Disease
Test Drug

Participate Sites
7Sites

Terminated6Sites

鍾飲文

Kaohsiung Municipal Gangshan Hospital

未分科

2017-08-01 - 2022-12-31

Phase III

Not yet recruiting

A Phase III, Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Of Pracinostat In Combination With Azacitidine In Patients ≥18 Years With Newly Diagnosed Acute Myeloid Leukemia Unfit For Standard Induction Chemotherapy

Condition/Disease

Acute Myeloid Leukemia (AML)
Test Drug

Pracinostat

Participate Sites
9Sites

Terminated7Sites

2015-10-01 - 2017-07-31

Phase I/II

Completed

Condition/Disease
Test Drug

Participate Sites
6Sites

Terminated4Sites

陳彥旭

Kaohsiung Municipal Gangshan Hospital

未分科

2016-09-01 - 2020-11-09

Phase II

A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY OF THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE IN COMBINATION WITH ATEZOLIZUMAB OR ATEZOLIZUMAB-PLACEBO IN PATIENTS WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR TRASTUZUMAB AND TAXANE BASED THERAPY.

Condition/Disease

HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER
Test Drug

KADCYLA

Participate Sites
10Sites

Terminated8Sites

侯明鋒

Kaohsiung Municipal Gangshan Hospital

未分科

曾令民

Taipei Veterans General Hospital

Division of General Surgery

2016-02-21 - 2020-12-31

Phase III

A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH NAB-PACLITAXEL COMPARED WITH PLACEBO WITH NAB-PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC TRIPLE NEGATIVE BREAST CANCER

Condition/Disease

Triple Negative Breast Cancer (TNBC)
Test Drug

Atezolizumab

Participate Sites
6Sites

Not yet recruiting1Sites

Terminated3Sites

侯明鋒

Kaohsiung Municipal Gangshan Hospital

未分科

曾令民

Taipei Veterans General Hospital

Division of General Surgery

2019-03-01 - 2023-10-07

Phase II

The HIV Functional Cure Potential of UB-421: A Phase II, Randomized, Open-label, Controlled, 48 Week, Proof of Concept Study, to Evaluate the Safety of UB-421 in Combination With Standard Antiretroviral Therapy (ART) and the Efficacy of HIV Reservoir Reduction as Compared With ART Alone in ART Stabilized HIV-1 Patients

Condition/Disease

HIV-1 Infection
Test Drug

UB-421

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting4Sites

陳彥旭

Kaohsiung Municipal Gangshan Hospital

未分科

2017-05-15 - 2020-04-09

Phase III

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects With Extensive Stage Small Cell Lung Cancer (MERU)

Condition/Disease

Extensive Stage Small Cell Lung Cancer
Test Drug

Rovalpituzumab Tesirine(Rova-T)

Participate Sites
9Sites

Terminated8Sites

洪仁宇

Kaohsiung Municipal Gangshan Hospital

未分科

邱昭華

Taipei Veterans General Hospital

Division of Hematology & Oncology

2015-10-01 - 2019-05-15

Phase III

An international, multicenter, randomized, double-blind, placebo-controlled phase 3 trial investigating the efficacy and safety of rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease undergoing lower extremity revascularization procedures

Condition/Disease

Symptomatic peripheral artery disease
Test Drug

Xarelto tablet

Participate Sites
8Sites

Terminated7Sites

林宗憲

Kaohsiung Municipal Gangshan Hospital

未分科

江晨恩

Taipei Veterans General Hospital

Search Result

List